Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study.

ABSTRACT: The therapeutic landscape for advanced melanoma has recently been transformed by several novel agents (immune checkpoint inhibitors and molecular-targeted agents). The prospective, multi-site, observational study IMAGE (ipilimumab: management of advanced melanoma in real practice) included a retrospective cohort to describe real-world treatment prior to approval of the immune checkpoint inhibitor ipilimumab. This retrospective cohort of patients, who started second-line/subsequent treatment (index therapy) for advanced melanoma within 3 years before ipilimumab approval, was selected randomly by chart review. Collected data included treatment history, patient outcomes, and healthcare resource utilization. All patients had ≥1 year of follow-up data. This analysis included 177 patients from E

SUBMITTER: Middleton MR 

PROVIDER: S-EPMC4944869 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature